York life sciences business, OptiBiotix Health, has signed a five-year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products containing LPLDL, its cholesterol and blood pressure reducing strain, in India.
The company said the agreement is a strategic step to extend the opportunities offered by LPLDL into India and Southern Asia.
As per the agreement, Akums, India’s largest contract manufacturing organisation, will manufacture and supply products containing OptiBiotix’s LPLDL throughout India to maximise the financial return for both parties.
In return for exclusivity, Akums will provide undisclosed and in-kind contributions and will explore the opportunities to utilise LPLDL with OptiBiotix for biotherapeutics in India.
OptiBiotix CEO Stephen O’Hara said: “This agreement is a strategic step to add manufacturing to the supply chain in the Asian probiotic supplement and pharmaceutical market and extends the commercial reach of OptiBiotix’s LPLDL strain into Southern Asia.
“This allows OptiBiotix to offer multiple product solutions to consumer health and pharmaceutical companies within the region.
“This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, white label and own label branded consumer and pharmaceutical products, across multiple channels, with leading industry partners from around the world.”